Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

PHASE2CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
PTSD
Interventions
DRUG

TNX-102 SL

DRUG

Placebo

Trial Locations (23)

11516

Cedarhurst, Cedarhurst

30308

Atlanta Center For Medical Research, Atlanta

32025

Sarkis Clinical Trials, Lake City

32801

Clinical Neuroscience Solutions, Inc., Orlando

34748

Compass Research North, LLC, Leesburg

35404

Tuscaloosa VA Medical Center, Tuscaloosa

44106

University Hospitals Case Medical Center, Cleveland

45219

Cincinnati, Cincinnati

60640

Great Lakes Clinical Trials, Chicago

68526

Premier Psychiatric Research Institute, Inc., Lincoln

73103

IPS Research Company, Oklahoma City

78229

Clinical Trials of Texas, San Antonio

85032

Noesis Pharma, Phoenix

89102

Altea Research, Las Vegas

90502

Cns, Inc., Torrance

91950

National City, National City

92161

Veteran Affairs, San Diego Health Care System, San Diego

92251

Sun Valley Research Center, Imperial

92506

Excell Research, Inc, Oceanside

CITRIALS, Riverside

92868

Neuropsychiatric Research Center of Orange County, Orange

98007

Northwest Clinical Research Center, Bellevue

02740

Novex Clinical Research, New Bedford

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT02277704 - Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions | Biotech Hunter | Biotech Hunter